Skip to main content
. 2020 Mar 24;4(6):1159–1165. doi: 10.1182/bloodadvances.2019001165

Table 1.

Patient demographics

Placebo (n = 21) Montelukast (n = 20) P
Male, n (%) 8 (38) 9 (45) .76
Age, median (range), y 27 (19-52) 26.5 (16-64) .96
Hospitalizations in last 3 y, n 2 (0-3) 3 (1.5-7) .13
ED visits in last 3 y, n 2 (1-4) 5 (1.5-7) .16
Admissions for pain crises in last 3 y, n 7.5 (4-15) 10 (6.5-20) .46
WBC, ×109/L 7.1 (5.5-8.6) 7.6 (5.5-9.4) .50
Hb, g/dL 8.7 (8.2-9.7) 9.1 (8.3-9.9) .34
Reticulocyte count (%), % 8.85 (5.50-13.1) 9.15 (8.35-9.9) .53

Hb, hemoglobin; WBC, white blood cell count.

Unless otherwise noted, data are median (IQR).